Comparing two drug combinations for certain types of AML and high-risk MDS
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two combinations of chemotherapy drugs to see which one works better for people with certain types of acute myeloid leukemia (AML) or a high-risk bone marrow disorder called MDS. The goal is to find a treatment that may help control the disease and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of AML or high-risk MDS (MDS-IB2).
- For people with AML, you must meet one of these: have AML related to previous treatment, had MDS before, have certain genetic changes, had CMML, be 60 or older, or have had a blood disease like ET, PV, or MF.
- If you are 60 or older, you must be generally fit (able to take care of yourself, no severe health problems).
- Your liver and kidney function must be within acceptable limits.
- You cannot have had certain previous treatments, such as mitoxantrone, venetoclax, or high doses of certain chemotherapy drugs.
- Your heart must be in good shape (no significant heart problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different combinations of chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). One combination uses newer targeted drugs, while the other is a standard treatment. The goal is to see which approach works better.
This trial tests a combination of three drugs for treating newly diagnosed AML in older or frailer patients. The goal is to see if this combination is safe and effective, providing a gentler option for those who cannot handle standard intensive chemotherapy.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
This study compares two chemotherapy combinations for older adults newly diagnosed with acute myeloid leukemia (AML) that has certain gene changes (NPM1 or IDH1/IDH2). The goal is to see if the new combination works better and has fewer side effects than the standard one.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.